Gene therapy holds much promise for the treatment of many human diseases. Research focused on improving vector delivery systems, identifying therapeutic genes and designing effective treatment regimens, continues. Meanwhile, many first generation gene therapy products are being evaluated in early ph
CTL quality and the control of human retroviral infections
β Scribed by Charles R. M. Bangham
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 188 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The CTL response plays a central part in deciding the outcome of viral infections. Evidence from host and viral genetics, gene expression microarrays and assays of Tβcell phenotype and function indicate that individual differences in the efficiency of the virusβspecific CTL response strongly determine the outcome of infection with the human retroviruses HTLVβ1 and HIVβ1. It is now believed that differences in antiβviral CTL efficiency or βqualityβ at the singleβcell level are critical in determining the efficacy of the host response to viruses. However, it is difficult to identify and quantify the reasons for this apparent individual variation in CTL efficiency, because of the chronic course of infection and the dynamical complexity of the equilibrium that is established between the virus and the host immune response. Specifically, it is unclear whether the observed variations among infected hosts, i.e. in the frequency, phenotype and function or quality of T cells, are the causes or effects β or both β of the variation in the efficiency of virus control.
π SIMILAR VOLUMES
Lymphocytic choriomeningitis virus (LCMV) infection in mice provides an example of an extraordinarily dynamic process with an extreme sensitivity of phenotype of infection to parameters of virus/host interaction. A mathematical model is developed to examine the dynamics of virus-specific cytotoxic T